Albireo to Present at the William Blair Biotech Focus Conference 2021
Albireo Pharma (Nasdaq: ALBO) announced that CEO Ron Cooper will present at the William Blair Biotech Focus Conference on July 15, 2021, at 11:00 a.m. EDT. The presentation will be streamed live on Albireo’s website, with an archived version available for 30 days post-event. Albireo focuses on novel bile acid modulators for rare liver diseases. Its lead candidate, Bylvay, is under Phase 3 trials for pediatric cholestatic liver diseases. The FDA has granted Priority Review for Bylvay, with a PDUFA date set for July 20, 2021.
- None.
- None.
BOSTON, July 08, 2021 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a rare liver disease company developing novel bile acid modulators, today announced that Ron Cooper, President and Chief Executive Officer, will present at the William Blair Biotech Focus Conference on Thursday, July 15, at 11:00 a.m. EDT.
The live webcast of the presentation will be accessible from the Media & Investors page of Albireo’s website, ir.albireopharma.com. To ensure a timely connection to the webcast, it is recommended that users register at least 15 minutes prior to the scheduled start time. An archived version of the webcasts will be available for replay in the Events & Presentations section of the Media & Investors page of Albireo’s website for 30 days following the event.
About Albireo
Albireo Pharma is a clinical-stage biopharmaceutical company focused on the development of novel bile acid modulators to treat rare pediatric and adult liver diseases. Albireo’s lead product candidate, Bylvay, is being developed to treat rare pediatric cholestatic liver diseases with Phase 3 trials in PFIC, Alagille syndrome and biliary atresia. For PFIC, the FDA recently granted Priority Review and set a PDUFA goal date of July 20, 2021. In Europe, the EMA’s CHMP recently issued a positive opinion and Bylvay is the only IBATi granted accelerated assessment by the EMA. Bylvay has been provisionally accepted by both the FDA and EMA as the brand name for odevixibat. The Company has also initiated a Phase 1 clinical trial for A3907 to advance development in adult cholestatic liver disease, with IND-enabling studies moving ahead with A2342 for viral and cholestatic liver disease. Albireo was spun out from AstraZeneca in 2008 and is headquartered in Boston, Massachusetts, with its key operating subsidiary in Gothenburg, Sweden. The Boston Business Journal named Albireo one of the 2020 Best Places to Work in Massachusetts for the second consecutive year. For more information on Albireo, please visit www.albireopharma.com.
Media Contact:
Colleen Alabiso, 857-356-3905, colleen.alabiso@albireopharma.com
Lisa Rivero, 617-947-0899, lisa.rivero@syneoshealth.com
Investor Contact:
Hans Vitzthum, LifeSci Advisors, LLC., 617-430-7578
FAQ
What is Albireo Pharma's presentation date at the William Blair Biotech Focus Conference?
What time will Albireo Pharma present at the William Blair Biotech Focus Conference?
Where can I watch the presentation by Albireo Pharma?
What is the PDUFA date for Albireo Pharma's Bylvay?
What diseases is Albireo Pharma's Bylvay being developed to treat?
